Harrow Health/$HROW

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Harrow Health

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.

Ticker

$HROW
Sector
Primary listing

Employees

382

Harrow Health Metrics

BasicAdvanced
$1.5B
-
-$0.29
0.33
-

What the Analysts think about Harrow Health

Analyst ratings (Buy, Hold, Sell) for Harrow Health stock.

Bulls say / Bears say

Harrow reported Q2 2025 revenue of $63.7 million, up 30% year-on-year, and adjusted EBITDA of $17.0 million, demonstrating strong leverage and improved profitability (GlobeNewswire)
VEVYE captured almost 3% market share in Q2, with sequential prescription growth of 66% and around 50,000 new prescriptions, indicating robust commercial uptake (GlobeNewswire)
In June 2025, Harrow obtained exclusive U.S. rights to BYQLOVI™, the first FDA-approved ophthalmic steroid in its class in 15 years, entering the $500 million-plus post-surgical inflammation market (Business Wire)
Harrow’s Q2 revenue of $63.7 million fell short of the $66 million consensus estimate, pointing to potential pricing or demand headwinds despite strong annual growth (Investing.com)
VEVYE's sequential revenue dropped to $18.6 million in Q2 from $21.5 million in Q1, as the VEVYE Access for All program pressured average selling prices, raising concerns over margin compression (Investing.com)
With H1 2025 revenue at $111.6 million versus full-year guidance exceeding $280 million, Harrow needs to generate roughly $169 million in H2—over 60% of the annual target in six months—posing execution challenges (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

Harrow Health Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Harrow Health Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HROW

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs